Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;236(4):2459-2481.
doi: 10.1002/jcp.30064. Epub 2020 Sep 22.

CRISPR/Cas gene therapy

Baohong Zhang  1
Affiliations
Review

CRISPR/Cas gene therapy

Baohong Zhang. J Cell Physiol. 2021 Apr.

Abstract

Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated enzyme (Cas) is a naturally occurring genome editing tool adopted from the prokaryotic adaptive immune defense system. Currently, CRISPR/Cas9-based genome editing has been becoming one of the most promising tools for treating human genetic diseases, including cardiovascular diseases, neuro-disorders, and cancers. As the quick modification of the CRISPR/Cas9 system, including delivery system, CRISPR/Cas9-based gene therapy has been extensively studied in preclinic and clinic treatments. CRISPR/Cas genome editing is also a robust tool to create animal genetic models for studying and treating human genetic disorders, particularly diseases associated with point mutations. However, significant challenges also remain before CRISPR/Cas technology can be routinely employed in the clinic for treating different genetic diseases, which include toxicity and immune response of treated cells to CRISPR/Cas component, highly throughput delivery method, and potential off-target impact. The off-target effect is one of the major concerns for CRISPR/Cas9 gene therapy, more research should be focused on limiting this impact by designing high specific gRNAs and using high specificity of Cas enzymes. Modifying the CRISPR/Cas9 delivery method not only targets a specific tissue/cell but also potentially limits the off-target impact.

Keywords: CRISPR/Cas9; animal model; gene therapy; genetic disease; genetic disorder; genome editing.

PubMed Disclaimer

References

REFERENCES

    1. Adikusuma, F., Piltz, S., Corbett, M. A., Turvey, M., McColl, S. R., Helbig, K. J., Beard, M. R., Hughes, J., Pomerantz, R. T., & Thomas, P. Q. (2018). Large deletions induced by Cas9 cleavage. Nature, 560, E8-E9.
    1. Adli, M. (2018). The CRISPR tool kit for genome editing and beyond. Nature Communications, 9, 9.
    1. Ahfeldt, T., Ordureau, A., Bell, C., Sarrafha, L., Sun, C., Piccinotti, S., Grass, T., Parfitt, G. M., Paulo, J. A., Yanagawa, F., Uozumi, T., Kiyota, Y., Harper, J. W., & Rubin, L. L. (2020). Pathogenic pathways in early-onset autosomal recessive Parkinson's disease discovered using isogenic human dopaminergic neurons. Stem Cell Reports, 14, 75-90.
    1. Allen, A. G., Chung, C.-H., Atkins, A., Dampier, W., Khalili, K., Nonnemacher, M. R., & Wigdahl, B. (2018). Gene editing of HIV-1 co-receptors to prevent and/or cure virus infection. Frontiers in Microbiology, 9, 2940.
    1. Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., & Liu, D. R. (2019). Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 576, 149-157.

MeSH terms

Substances

LinkOut - more resources